Literature DB >> 27340326

Nintedanib.

.   

Abstract

Entities:  

Keywords:  idiopathic pulmonary fibrosis; nintedanib; non-small cell lung cancer

Year:  2016        PMID： 27340326      PMCID： PMC4917623          DOI： 10.18773/austprescr.2016.031

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  2 in total

1.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

2.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245
  2 in total
  1 in total

1.  Synthetically lethal nanoparticles for treatment of endometrial cancer.

Authors:  Kareem Ebeid; Xiangbing Meng; Kristina W Thiel; Anh-Vu Do; Sean M Geary; Angie S Morris; Erica L Pham; Amaraporn Wongrakpanich; Yashpal S Chhonker; Daryl J Murry; Kimberly K Leslie; Aliasger K Salem
Journal:  Nat Nanotechnol       Date:  2017-12-04       Impact factor: 39.213
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.